Kubota Pharmaceutical Holdings Co., Ltd. operates globally, concentrating on the development of innovative drugs and medical devices within the ophthalmology sector. A key asset in its product pipeline is emixustat hydrochloride, which is currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. The company is also advancing a remote, patient self-monitoring optical coherence tomography (OCT) device designed for home use, intended to address conditions like wet age-related macular degeneration and diabetic macular edema, which are characterized by retinal swelling and reduced visual acuity.